Please check out SNTA's December overview on their webside. Slide 7 shows that SNTA projects $2 billion of annual sales for ganetespib for 2nd line lung cancer (in combo w/ chemotherapy). Slides 34-38 show how outstanding the Phase 2b interim results were, including a ganetespib Hazard Ratio of only 0.37. (The Phase 3 trial will be 99% powered assuming a much higher Hazard Ratio of 0.60). If the interim results hold up, ganetespib will add an average of around 12 months of life for adeno-non-rapidly-progressing lung cancer pateints (19 months instead of 7 months)! This is pretty remarkable.
And this doesn't include ganetespib's potential in 1st line lung cancer, as a monotherapy, in other combinations (including radiation) and in many other cancers. It doesn't include elesclomol and the rest of the pipeline either.
And it doesn't hurt that the insiders have been buying and that certain insiders have very deep pockets.